285 related articles for article (PubMed ID: 30243944)
1. A study on the role of cholesterol and phosphatidylcholine in various features of liposomal doxorubicin: From liposomal preparation to therapy.
Farzaneh H; Ebrahimi Nik M; Mashreghi M; Saberi Z; Jaafari MR; Teymouri M
Int J Pharm; 2018 Nov; 551(1-2):300-308. PubMed ID: 30243944
[TBL] [Abstract][Full Text] [Related]
2. The impact of phospholipids with high transition temperature to enhance redox-sensitive liposomal doxorubicin efficacy in colon carcinoma model.
Mirhadi E; Askarizadeh A; Farhoudi L; Mashreghi M; Behboodifar S; Alavizadeh SH; Arabi L; Jaafari MR
Chem Phys Lipids; 2024 Jul; 261():105396. PubMed ID: 38621603
[TBL] [Abstract][Full Text] [Related]
3. Lipid-polymer hybrid nanoparticles as a new generation therapeutic delivery platform: a review.
Hadinoto K; Sundaresan A; Cheow WS
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):427-43. PubMed ID: 23872180
[TBL] [Abstract][Full Text] [Related]
4. Investigation of Hexadecylphosphocholine (miltefosine) usage in Pegylated liposomal doxorubicin as a synergistic ingredient: In vitro and in vivo evaluation in mice bearing C26 colon carcinoma and B16F0 melanoma.
Teymouri M; Farzaneh H; Badiee A; Golmohammadzadeh S; Sadri K; Jaafari MR
Eur J Pharm Sci; 2015 Dec; 80():66-73. PubMed ID: 26299343
[TBL] [Abstract][Full Text] [Related]
5. Poly(ethylene glycol)-induced and temperature-dependent phase separation in fluid binary phospholipid membranes.
Lehtonen JY; Kinnunen PK
Biophys J; 1995 Feb; 68(2):525-35. PubMed ID: 7696506
[TBL] [Abstract][Full Text] [Related]
6. Optimized thermosensitive liposomes for selective doxorubicin delivery: formulation development, quality analysis and bioactivity proof.
Levacheva I; Samsonova O; Tazina E; Beck-Broichsitter M; Levachev S; Strehlow B; Baryshnikova M; Oborotova N; Baryshnikov A; Bakowsky U
Colloids Surf B Biointerfaces; 2014 Sep; 121():248-56. PubMed ID: 25001189
[TBL] [Abstract][Full Text] [Related]
7. Liposomal doxorubicin circumvents PSC 833-free drug interactions, resulting in effective therapy of multidrug-resistant solid tumors.
Krishna R; Mayer LD
Cancer Res; 1997 Dec; 57(23):5246-53. PubMed ID: 9393743
[TBL] [Abstract][Full Text] [Related]
8. Improvement in the drug delivery and anti-tumor efficacy of PEGylated liposomal doxorubicin by targeting RNA aptamers in mice bearing breast tumor model.
Moosavian SA; Abnous K; Badiee A; Jaafari MR
Colloids Surf B Biointerfaces; 2016 Mar; 139():228-36. PubMed ID: 26722819
[TBL] [Abstract][Full Text] [Related]
9. Role of drug release and liposome-mediated drug delivery in governing the therapeutic activity of liposomal mitoxantrone used to treat human A431 and LS180 solid tumors.
Lim HJ; Masin D; McIntosh NL; Madden TD; Bally MB
J Pharmacol Exp Ther; 2000 Jan; 292(1):337-45. PubMed ID: 10604968
[TBL] [Abstract][Full Text] [Related]
10. Novel temperature-triggered liposome with high stability: formulation, in vitro evaluation, and in vivo study combined with high-intensity focused ultrasound (HIFU).
Park SM; Kim MS; Park SJ; Park ES; Choi KS; Kim YS; Kim HR
J Control Release; 2013 Sep; 170(3):373-9. PubMed ID: 23770213
[TBL] [Abstract][Full Text] [Related]
11. Increased intracellular drug accumulation and complete chemosensitization achieved in multidrug-resistant solid tumors by co-administering valspodar (PSC 833) with sterically stabilized liposomal doxorubicin.
Krishna R; St-Louis M; Mayer LD
Int J Cancer; 2000 Jan; 85(1):131-41. PubMed ID: 10585596
[TBL] [Abstract][Full Text] [Related]
12. Drug release rate influences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer.
Charrois GJ; Allen TM
Biochim Biophys Acta; 2004 May; 1663(1-2):167-77. PubMed ID: 15157619
[TBL] [Abstract][Full Text] [Related]
13. Liposomal Doxorubicin Delivery Systems: Effects of Formulation and Processing Parameters on Drug Loading and Release Behavior.
Mohammadi ZA; Aghamiri SF; Zarrabi A; Talaie MR
Curr Drug Deliv; 2016; 13(7):1065-1070. PubMed ID: 26708673
[TBL] [Abstract][Full Text] [Related]
14. Formation of transition metal-doxorubicin complexes inside liposomes.
Abraham SA; Edwards K; Karlsson G; MacIntosh S; Mayer LD; McKenzie C; Bally MB
Biochim Biophys Acta; 2002 Sep; 1565(1):41-54. PubMed ID: 12225851
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and therapeutics of sterically stabilized liposomes in mice bearing C-26 colon carcinoma.
Huang SK; Mayhew E; Gilani S; Lasic DD; Martin FJ; Papahadjopoulos D
Cancer Res; 1992 Dec; 52(24):6774-81. PubMed ID: 1458465
[TBL] [Abstract][Full Text] [Related]
16. Intratumor distribution of doxorubicin following i.v. administration of drug encapsulated in egg phosphatidylcholine/cholesterol liposomes.
Harasym TO; Cullis PR; Bally MB
Cancer Chemother Pharmacol; 1997; 40(4):309-17. PubMed ID: 9225948
[TBL] [Abstract][Full Text] [Related]
17. In vivo anti-tumor effect of PEG liposomal doxorubicin (DOX) in DOX-resistant tumor-bearing mice: Involvement of cytotoxic effect on vascular endothelial cells.
Ogawara K; Un K; Tanaka K; Higaki K; Kimura T
J Control Release; 2009 Jan; 133(1):4-10. PubMed ID: 18840484
[TBL] [Abstract][Full Text] [Related]
18. Doxorubicin liposomes as an investigative model to study the skin permeation of nanocarriers.
Boakye CH; Patel K; Singh M
Int J Pharm; 2015 Jul; 489(1-2):106-16. PubMed ID: 25910414
[TBL] [Abstract][Full Text] [Related]
19. A single dose of doxorubicin-functionalized bow-tie dendrimer cures mice bearing C-26 colon carcinomas.
Lee CC; Gillies ER; Fox ME; Guillaudeu SJ; Fréchet JM; Dy EE; Szoka FC
Proc Natl Acad Sci U S A; 2006 Nov; 103(45):16649-54. PubMed ID: 17075050
[TBL] [Abstract][Full Text] [Related]
20. Formulation kit for liposomal doxorubicin composed of lyophilized liposomes.
Stevens PJ; Lee RJ
Anticancer Res; 2003; 23(1A):439-42. PubMed ID: 12680245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]